Krystal Biotech Inc (KRYS)

$272.52 +4.48 (1.67%)
Market Cap 7.89B
Revenue (ttm) 389.13M
Net Income (ttm) 204.83M
EPS (ttm) N/A
PE Ratio 40.28
Forward PE 35.54
Profit Margin 52.64%
Debt to Equity Ratio 0.00
Volume 264,100
Avg Vol 290,750
Day's Range N/A - N/A
Shares Out 29.44M
Stochastic %K 67%
Beta 0.54
Analysts Strong Sell
Price Target $325.90

Company Profile

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical tri...

Industry: Biotechnology
Sector: Healthcare
Phone: 412 586 5830
Address:
2100 Wharton Street, Suite 701, Pittsburgh, United States
IN0V8
IN0V8 Apr. 20 at 7:27 PM
$KRYS Buy Jefferies raises target price to $380 from $371
0 · Reply
MeanReverter_
MeanReverter_ Apr. 18 at 5:56 PM
$KRYS PIPELINE STACKED = MULTIPLE CATALYST WINDOWS INTO 2026 This isn’t a one-shot biotech — it’s a multi-event setup with staggered upside triggers. • KB801 (Neurotrophic Keratitis) → Phase 3 EMERALD-1 readout by YE26 • KB407 (Cystic Fibrosis) → CORAL-3 enrollment kicks off 1H26 • KB408 (AATD) → SERPENTINE-1 Cohort 2B repeat-dose interim data incoming • KB803 (DEB corneal abrasions) → Phase 3 enrollment wraps 1H26, topline by YE26 Translation: constant news flow + re-rating opportunities. Biotech runs on catalysts — and $KRYS is lining up a full calendar. Any positive data here can shift sentiment FAST, especially with multiple shots on goal. Watch positioning into each milestone window
0 · Reply
GECE
GECE Apr. 15 at 6:50 AM
$KRYS damn. Should have hold this one when I bought at 30 and sold at 60…
0 · Reply
1GreenDay99RedDays
1GreenDay99RedDays Mar. 2 at 8:43 PM
$KRYS been a monster for 5 years i comment and blamo
0 · Reply
GorillaTrades
GorillaTrades Feb. 27 at 8:22 PM
Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Cboe Global Markets $CBOE +4.7%, Krystal Biotechnology $KRYS +4.7%, and Agree Realty $ADC +3.5%
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 10:34 PM
$KRYS RSI: 52.04, MACD: 1.0698 Vol: 6.74, MA20: 273.76, MA50: 265.48 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
erevnon
erevnon Feb. 25 at 2:57 PM
Guggenheim maintains Krystal Biotech $KRYS at Buy and raises the price target from $224 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Theflash88
Theflash88 Feb. 22 at 9:01 PM
$KRYS Well that big rally didn’t last long.
0 · Reply
wheresdannynow
wheresdannynow Feb. 20 at 8:22 PM
$KRYS is crushing it with Vyjuvek sales and pipeline wins. That’s what biotech patience looks like when it pays. While big caps like $LLY $NVO stay crowded, small caps can reprice hard when data lines up. $BIOV.CSE $BVAXF quietly stacking positive DPX data in ovarian, bladder, and breast cancer. Platform stories heat up fast once momentum builds. Biotech does not reward panic. It rewards positioning.
0 · Reply
Ventureville
Ventureville Feb. 20 at 3:57 PM
Q1 2026 is already lighting up biotech. $MBRX accelerating its AML trial. $KRYS beating on earnings. Multiple FDA decisions lined up across the sector. When biotech momentum builds, small caps move fast. $BIOV.CSE $BVAXF with HapTenix and BVX-0918 in ovarian cancer sits right in that wave. Rotation into biotech does not trickle. It snaps.
0 · Reply
Latest News on KRYS
Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026

Apr 21, 2026, 8:00 AM EDT - 4 days ago

Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

Feb 17, 2026, 7:00 AM EST - 2 months ago

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

Feb 10, 2026, 8:00 AM EST - 2 months ago

Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

These under-the-radar stocks combine fast growth with big upside potential

Jan 15, 2026, 10:31 AM EST - 3 months ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CORT CTRE DCOM DOCN

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 1:00 PM EST - 3 months ago

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

Nov 26, 2025, 8:00 AM EST - 5 months ago

Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin

Sep 15, 2025, 1:39 PM EDT - 7 months ago

FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin

Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

Sep 15, 2025, 8:00 AM EDT - 7 months ago

Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

Aug 21, 2025, 12:11 PM EDT - 8 months ago

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

Jul 25, 2025, 9:00 AM EDT - 9 months ago

Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

Jul 24, 2025, 8:00 AM EDT - 9 months ago

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

Jul 9, 2025, 7:00 AM EDT - 10 months ago

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

Jun 24, 2025, 7:00 AM EDT - 10 months ago

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

Krystal Biotech to Present at BofA Securities 2025 Health Care Conference

May 7, 2025, 8:00 AM EDT - 1 year ago

Krystal Biotech to Present at BofA Securities 2025 Health Care Conference

Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Apr 28, 2025, 7:00 AM EDT - 1 year ago

Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech to Present at Upcoming Scientific Conferences

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Krystal Biotech to Present at Upcoming Scientific Conferences

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

Apr 7, 2025, 4:30 PM EDT - 1 year ago

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Feb 28, 2025, 7:40 AM EST - 1 year ago

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 19, 2025, 7:00 AM EST - 1 year ago

Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

Feb 18, 2025, 10:20 AM EST - 1 year ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK CYTK EXE MARA MP

Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

Jan 14, 2025, 8:00 AM EST - 1 year ago

Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

Dec 18, 2024, 8:00 AM EST - 1 year ago

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

Krystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

Dec 9, 2024, 4:15 PM EST - 1 year ago

Krystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

Krystal Biotech to Present at Upcoming Investor Conferences

Nov 27, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech to Present at Upcoming Investor Conferences

Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

Nov 6, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024

Oct 28, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024

Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference

Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

Jul 26, 2024, 8:00 AM EDT - 1 year ago

Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

Krystal Biotech to Present at the American Thoracic Society 2024 International Conference

May 15, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech to Present at the American Thoracic Society 2024 International Conference

Krystal Biotech to Present at BofA Securities 2024 Health Care Conference

May 8, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech to Present at BofA Securities 2024 Health Care Conference

Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates

May 6, 2024, 8:00 AM EDT - 2 years ago

Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates

Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

May 2, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024

Apr 26, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

Apr 22, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

Apr 4, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

Feb 28, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Feb 26, 2024, 8:00 AM EST - 2 years ago

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

Feb 20, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung

Feb 13, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung

Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa

Feb 8, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa

Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference

Feb 1, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference

Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®

Jan 4, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®

Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)

Dec 19, 2023, 7:00 AM EST - 2 years ago

Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa

Nov 27, 2023, 7:00 AM EST - 2 years ago

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech to Present at the Stifel 2023 Healthcare Conference

Nov 9, 2023, 7:00 AM EST - 2 years ago

Krystal Biotech to Present at the Stifel 2023 Healthcare Conference

Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 7:00 AM EST - 2 years ago

Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update

Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023

Oct 30, 2023, 7:00 AM EDT - 2 years ago

Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023

Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference

Sep 28, 2023, 7:00 AM EDT - 2 years ago

Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference

Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency

Sep 21, 2023, 9:00 AM EDT - 2 years ago

Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency

IN0V8
IN0V8 Apr. 20 at 7:27 PM
$KRYS Buy Jefferies raises target price to $380 from $371
0 · Reply
MeanReverter_
MeanReverter_ Apr. 18 at 5:56 PM
$KRYS PIPELINE STACKED = MULTIPLE CATALYST WINDOWS INTO 2026 This isn’t a one-shot biotech — it’s a multi-event setup with staggered upside triggers. • KB801 (Neurotrophic Keratitis) → Phase 3 EMERALD-1 readout by YE26 • KB407 (Cystic Fibrosis) → CORAL-3 enrollment kicks off 1H26 • KB408 (AATD) → SERPENTINE-1 Cohort 2B repeat-dose interim data incoming • KB803 (DEB corneal abrasions) → Phase 3 enrollment wraps 1H26, topline by YE26 Translation: constant news flow + re-rating opportunities. Biotech runs on catalysts — and $KRYS is lining up a full calendar. Any positive data here can shift sentiment FAST, especially with multiple shots on goal. Watch positioning into each milestone window
0 · Reply
GECE
GECE Apr. 15 at 6:50 AM
$KRYS damn. Should have hold this one when I bought at 30 and sold at 60…
0 · Reply
1GreenDay99RedDays
1GreenDay99RedDays Mar. 2 at 8:43 PM
$KRYS been a monster for 5 years i comment and blamo
0 · Reply
GorillaTrades
GorillaTrades Feb. 27 at 8:22 PM
Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Cboe Global Markets $CBOE +4.7%, Krystal Biotechnology $KRYS +4.7%, and Agree Realty $ADC +3.5%
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 25 at 10:34 PM
$KRYS RSI: 52.04, MACD: 1.0698 Vol: 6.74, MA20: 273.76, MA50: 265.48 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
erevnon
erevnon Feb. 25 at 2:57 PM
Guggenheim maintains Krystal Biotech $KRYS at Buy and raises the price target from $224 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Theflash88
Theflash88 Feb. 22 at 9:01 PM
$KRYS Well that big rally didn’t last long.
0 · Reply
wheresdannynow
wheresdannynow Feb. 20 at 8:22 PM
$KRYS is crushing it with Vyjuvek sales and pipeline wins. That’s what biotech patience looks like when it pays. While big caps like $LLY $NVO stay crowded, small caps can reprice hard when data lines up. $BIOV.CSE $BVAXF quietly stacking positive DPX data in ovarian, bladder, and breast cancer. Platform stories heat up fast once momentum builds. Biotech does not reward panic. It rewards positioning.
0 · Reply
Ventureville
Ventureville Feb. 20 at 3:57 PM
Q1 2026 is already lighting up biotech. $MBRX accelerating its AML trial. $KRYS beating on earnings. Multiple FDA decisions lined up across the sector. When biotech momentum builds, small caps move fast. $BIOV.CSE $BVAXF with HapTenix and BVX-0918 in ovarian cancer sits right in that wave. Rotation into biotech does not trickle. It snaps.
0 · Reply
erevnon
erevnon Feb. 18 at 7:31 PM
Citigroup maintains Krystal Biotech $KRYS at Buy and raises the price target from $336 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
ZacksResearch
ZacksResearch Feb. 18 at 5:08 PM
$KRYS just delivered an earnings twist — beat on EPS, miss on revenue. So what really matters here? 👀 KRYS topped Q4 estimates while Vyjuvek sales jumped 17%, locked in 660+ U.S. reimbursements, and pushed its gene therapy pipeline runway into 2026. That’s operational momentum, even with revenues missing the mark. Is this a setup for longer-term upside or a mixed signal? Get the full breakdown 👉 https://www.zacks.com/stock/news/2871431/krystal-biotech-q4-earnings-beat-estimates-revenues-miss-mark?cid=sm-stocktwits-2-2871431-teaser-34052&ADID=SYND_STOCKTWITS_TWEET_2_2871431_TEASER_34052
0 · Reply
ZacksResearch
ZacksResearch Feb. 18 at 4:08 PM
$KRYS earnings beat! 🚀 What drove the growth? Krystal Biotech's Q4 EPS of $1.70 beat the Zacks Consensus Estimate of $1.62, with revenue up 17.5% in the reported quarter, thanks to strong Vyjuvek sales. The stock is up 63.4% over the past year! 📈 Find out what’s next for KRYS here 👉 https://www.zacks.com/stock/news/2871431/krystal-biotech-q4-earnings-beat-estimates-revenues-miss-mark?cid=sm-stocktwits-2-2871431-body-34049&ADID=SYND_STOCKTWITS_TWEET_2_2871431_BODY_34049
0 · Reply
erevnon
erevnon Feb. 18 at 2:25 PM
Chardan Capital maintains Krystal Biotech $KRYS at Buy and raises the price target from $220 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
mikesterz7
mikesterz7 Feb. 17 at 8:49 PM
$KRYS Krystal’s Vyjuvek is a gene therapy approved for the treatment of Dystrophic Epidermolysis Bullosa.
0 · Reply
StocktwitsNews
StocktwitsNews Feb. 17 at 8:21 PM
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism $KRYS $IJR $VTI https://stocktwits.com/news/equity/markets/krys-stock-rallies-on-upbeat-earnings-jefferies-ups-price-target/cZRWvWzR4HT
0 · Reply
1GreenDay99RedDays
1GreenDay99RedDays Feb. 17 at 6:57 PM
$KRYS honestly i cant think of a better looking chart in all of biotech than this, i made money here in 2021 and sold like a stunad congrats to all
0 · Reply
GitRichOrBuyTryin
GitRichOrBuyTryin Feb. 17 at 4:52 PM
$KRYS - Bought KRYS at $290 IBD buy point triggered at $286.52
0 · Reply
d_risk
d_risk Feb. 17 at 4:43 PM
$KRYS - Krystal Biotech Inc - 10K - Updated Risk Factors KRYS’s 2026 10-K sharpens risk around VYJUVEK dependence, global gene therapy commercialization and manufacturing scale-up (including ASTRA), intensifies focus on pricing/reimbursement, IP and patent litigation, cybersecurity and a 2024 incident, AI and data privacy laws, while adding detailed global regulatory, quality, executive loss, and capital/ownership concentration risks. #GeneTherapy #ManufacturingScale-Up #PricingRisk #IPLitigation #Cybersecurity 🟢 Added 🟠 Removed https://d-risk.ai/KRYS/10-K/2026-02-17
0 · Reply
OpenOutcrier
OpenOutcrier Feb. 17 at 1:59 PM
$KRYS (-1.2% pre) Krystal Biotech beats top-line and bottom-line estimates; initiates FY26 outlook https://ooc.bz/l/93538
0 · Reply
DonCorleone77
DonCorleone77 Feb. 17 at 12:30 PM
$KRYS Krystal Biotech sees FY26 non-GAAP R&D, SG&A expense $175M-$195M
0 · Reply
DonCorleone77
DonCorleone77 Feb. 17 at 12:29 PM
$KRYS Krystal Biotech reports Q4 EPS $1.70, consensus $1.61 Reports Q4 revenue $107.1M, consensus $105.13M. "In 2025, Krystal made meaningful progress on our mission to serve patients with dystrophic epidermolysis bullosa around the world, while continuing to build the global infrastructure required to scale our impact," said Krish S. Krishnan, Chairman and CEO of Krystal Biotech. "As we work toward our goal of launching multiple products and treating more than 10,000 patients living with rare diseases by the end of 2030, our recent cystic fibrosis readout further reinforces the versatility of our platform in high-turnover epithelial tissues. We believe we are still in the early stages of unlocking the transformational potential of our redosable HSV-1-based gene delivery platform, and we look forward to multiple registrational study readouts ahead across our rare disease pipeline."
0 · Reply